WO2019155389A1 - Composition mucoadhésive et bioadhésive aqueuse destinée au traitement - Google Patents

Composition mucoadhésive et bioadhésive aqueuse destinée au traitement Download PDF

Info

Publication number
WO2019155389A1
WO2019155389A1 PCT/IB2019/050971 IB2019050971W WO2019155389A1 WO 2019155389 A1 WO2019155389 A1 WO 2019155389A1 IB 2019050971 W IB2019050971 W IB 2019050971W WO 2019155389 A1 WO2019155389 A1 WO 2019155389A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrochloride
composition
acid
mucoadhesive
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2019/050971
Other languages
English (en)
Inventor
Marian BARTOSIEWICZ
Richard Trauger
John Ashley EADES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Target Oncology Inc
Original Assignee
Target Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Target Oncology Inc filed Critical Target Oncology Inc
Publication of WO2019155389A1 publication Critical patent/WO2019155389A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Definitions

  • the present invention relates to an aqueous mucoadhesive and bioadhesive compositions.
  • the present invention particularly relates to the application of the aforementioned composition for the prevention and/or treatment of mucosal diseases or disorders.
  • the dosage forms of the aforementioned composition sufficient ly used to coat a wide area of the mucosal surface, but are also bioadhesive and mucoadhesive useful to provide prolonged retention on the surface of the mucosa.
  • Skin and Mucous membranes provide a protective layer on the surface of sev eral body cavities, such as the oral cavity, the nasal cavity, the gastrointestinal and respiratory tracts, the vagina, and the bladder.
  • Cells within or glands adjacent to these membranes secrete mucus, a fluid or gel primarily composed of water, lipids, inorganic salts and mucin glycoproteins, which serve to form a protective barrier to inhibit passage of harmful materials to the underlying tissue.
  • mucus a fluid or gel primarily composed of water, lipids, inorganic salts and mucin glycoproteins
  • diseases in the oral cavity in clude aphthous ulcers, bullous pemphigoid, oral lichen planus, stomatopharyngitis, in Sjogren’s syndrome, oral mucositis, intestinal (nausea and vomiting, diarrhea, con stipation), vaginal (e.g. vaginitis, bacterial vaginosis) and rectal mucositis, mucous membrane contact dermatitis, and inflammation and dryness of the eye (e.g. keratitis sicca, conjunctivitis, dry eye disease, uveitis)
  • diseases of the nasal mu cous membrane include sinusitis and rhinitis; an example for the bladder is interstitial cystitis.
  • Certain diseases can affect the mucocutaneous membranes of several regions of the body.
  • Many other ulcerative, moisture loss, painful, or inflammatory mucocutaneous diseases are known, including xerostomia, stomatitis (including caused by certain medications, appliances such as CPAP ma- chines, etc.), and the like.
  • xerostomia including caused by certain medications, appliances such as CPAP ma- chines, etc.
  • stomatitis including caused by certain medications, appliances such as CPAP ma- chines, etc.
  • Aphthous ulcers also known as aphthous stomatitis and canker sores
  • Aphthous ulcers are be nign open sores in the mouth, which appears as a painful white or yellow sore (ulcer) surrounded by a bright red area.
  • Aphthous ulcers can be categorized into three groups:
  • Minor aphthous ulcers the most common type, which recur in crops of 1 to 5 lesions, are less than 1 cm in diameter each, and usually affect the lips, buccal mu cosa, mucobuccal and mucolabial sulci, and tongue;
  • Major aphthous ulcers which are greater than 2 cm in diameter, begin as soli tary nodules, and subsequently destroy deeper tissue, resulting in scarring that af fects the movable oral mucosa and posterior mucosal surfaces; and Herpetiform ul cers, which are recurrent, multiple (10 to 100), shallow, pinpoint lesions 1 to 2 mm in diameter that may affect any part of the mucosa. The cause for any of the three types is not known, although autoimmune mechanisms are suspected.
  • the cause can range from being well understood to unknown. There may be an inherited predisposition to their development. There may also be an immune sys tem link. Ulcers may develop in response to mouth injury such as dental procedures or aggressive tooth cleaning. They may occur at the site of a bite when the tongue or cheek is bitten. They can also triggered by stress, dietary deficiencies (especially iron, folic acid, or vitamin B12), menstrual periods, hormonal changes, food allergies, and similar situations. They may occur with no identifiable cause. Canker sores usu ally appear on nonkeratinized mouth tissue including the inner surface of the cheeks and lips, tongue, soft palate, and the base of the gums.
  • Behcet's disease is a chronic multisystem disease characterized by oral and genital aphthae, arthritis, cutaneous lesions, and ocular, gastrointestinal, and neuro logic manifestations. It was first described by the Turkish dermatologist Hulusi Behcet in 1937 as "recurrent oral aphthous ulcers, genital ulcers, and ' hypopyon- uveitis. The diagnosis of Behcet's disease is based on clinical criteria as estab lished by O'Duffy and Goldstein and the International Study Group. Complex aph- thosis is the presence of almost constant, multiple oral or oral and genital aphthae in the absence of systemic manifestations. These patients must be distinguished from those with Behcet's disease.
  • Behcet's disease is higher in the Middle East and Japan where it is approximately 1 in 1000. The disease is far less common in northern Eu rope, the United States, and the United Kingdom. The mean age of onset ranges from the mid to late 20s to the fourth decade, according to several series, with a slightly higher male to female ratio. It is relatively rare in children and the elderly. Behcet's disease is also uncommon among black Africans who, when they are af fected, tend to have more mucocutaneous features. Although a definitive pattern of inheritance has not been elucidated, familial cases have been reported.
  • Patients with complex aphthosis are probably a subset of patients with recurrent aphthous stoma titis, which is defined as the recurrence of 1 or more painful oral ulcers at intervals ranging from days to months.
  • the prevalence of recurrent aphthosis ranges from 5% to 66%. Onset may occur in childhood or adolescence and some patients experience a decrease in frequency with advancing age.
  • Bullous pemphigoid is an autoimmune, subepidermal blistering disease.
  • the antigenic targets are components of the hemidesmosome; the 230-kD bullous pemphigoid antigen 1 and the 180-kD bullous pemphigoid antigen 2. It commonly affects patients in their seventh decade. About 40% of patients will experience oral involvement during the course of their disease.
  • cystitis ' covers a range of disorders commonly known as "painful bladder” disease in which a subject suffers bladder and/or pelvic pain and irritative voiding symptoms (urgency, frequency, nocturia, dysuria).
  • pain bladder a range of disorders commonly known as "painful bladder” disease in which a subject suffers bladder and/or pelvic pain and irritative voiding symptoms (urgency, frequency, nocturia, dysuria).
  • causes which includes the damaging side-effects of radiation therapy to the lower abdomen, and cytotoxic agents and/or their metabolites as they pass through the bladder following renal clearance.
  • Cyclophosphamide (Cytoxan), the most commonly used oxazaphosphorine, is an alkylating agent first used in the treatment of malignant tumors in Europe in 1957. Cyclophosphamide still has a role in the treatment of solid tumors and lymphomas, as well as benign inflammatory states, Wegener's granulomatosis and rheumatoid arthritis being the most common. Other oxazaphosphorines--ifosfamide, trofospha- mide, and sufosfamide-have been used since the 1970s for the treatment of solid malignancies and lymphomas. Dose-limiting toxicity with these compounds is usually urinary tract toxicity.
  • urinary symptoms including frequency, urgency, dysuria, and nocturia develop in as many as 24% of patients treated with oral.
  • Bladder pathology has been attributed to toxic metabolites of these com pounds. Cyclophosphamide is broken down by hepatic microsomal cells to hy- droxycyclophosphamide; then by target cells to aldophosphamide; and then to phos- phoramide mustard, the active antineoplastic metabolite, and acrolein, which has no significant antitumor activity. Similarly, ifosfamide is metabolized to iphosphoramide mustard and acrolein. Urinary excretion of acrolein is believed to be the major source of urothelial toxicity. Most normal cells are able to break down the toxic metabolites and diminish their effect. Glutathione is a naturally occurring thiol that can confer such protection in most cells, but is present in low levels in urine.
  • Oxazaphosphorine toxicity has been demonstrated in several animal models with their systemic administration and by instillation of their normal metabolic prod ucts directly into the bladder. Urine from animals given these agents, when placed in other animal bladders, will reproduce these findings, while instillation of cyclophos phamide will not. Electron microscopy suggests the initial toxic effect is disruption of the plasma membrane and cytoplasmic matrix.
  • Bladder damage from these compounds is cumulative, and is generally dose related. "Cyclophosphamide cystitis" occurs frequently and early following intrave nous (IV) therapy, especially dose-intensive regimens. Cystitis usually takes weeks to develop after oral treatment, but has been seen after as little as one dose. Fibrosis has been found in as many as 25% of children receiving high-dose cyclophospha- mide. Severe hematuria and telangiectasia are more common in these patients. Ox- azaphosphorine cystitis is potentiated by prior pelvic radiation.
  • Cystoscopy may reveal a tumor or changes compatible with cyclophosphamide cystitis. Acutely diffuse inflammation is seen. Chronic changes include a pale bladder mucosa with telangiectasia. Areas of edema can be present with patchy hemorrhagic areas that stain with methylene blue, an indicator of mucosal injury. Biopsies reveal hyperemia, hemorrhage, edema, mucosal thinning, and ulceration of the urothelium. Necrosis of mucosa, muscle, and small arterioles and telangiectasia can be present. Atypia can be prominent, and abundant mitoses often occur. These findings are simi lar to those seen after radiation therapy. (Source: DeVita: Cancer: Principles and Practice of Oncology, 5th ed., Copyright.COPYRGT. 1997 Lippincott-Raven Publish ers).
  • Erythema multiforme often affects the oral cavity and is frequently recurrent.
  • the classic cutaneous findings are targetoid lesions symmetrically distributed over the trunk and extremities.
  • Studies show that as many as 70% of patients develop oral lesions, which are extremely painful and often debilitating.
  • HSV herpes simplex virus
  • Acyclovir or one of the newer antiviral agents can be used to suppress recurrent HSV outbreaks and to prevent recurrent erythema multiforme.
  • the current recom mendations for daily suppression of HSV are acyclovir (400 mg twice daily), famciclovir (250 mg twice daily), or alacyclovir (500 mg daily).
  • Suppressive doses are to be used for patients who experience more than six episodes a year of HSV or HSV-induced erythema multiforme.
  • Azathioprine can also be used to treat erythema multiforme. It should be used for patients who have severe mucosal involvement or in whom lesions con tinue to occur despite HSV suppression. In one study, 1 1 patients with severe dis ease failed to respond to acyclovir, dapsone, or antimalarials, but all cleared with az athioprine, 100 to 150 mg daily. Response was dose-dependent, and the condition relapsed when therapy was discontinued. Thalidomide has also been shown to be effective for recurrent erythema multiforme. (Source: J. L. Popovsky and C. Camisa, "New and emerging therapies for diseases of the oral cavity", Dermatologic Clinics, 2000, 18(1 ), 1 13-125.)
  • Esophagitis is a side-effect of the radiation therapy of the chest when the esophagus receives an unavoidable significant radiation dose.
  • Acute side effects occurring during the course of radiotherapy are organ spe cific and related to the fractionation scheme, total dose, and use of sequential or concomitant chemotherapy or radiosensitizers. They typically manifest in the second to third week of treatment.
  • a significant concern of combined therapy is the in creased toxicity, which may potentially outweigh the benefit from both modalities.
  • Interstitial cystitis (1C) has only recently been recognized as a major health problem. It encompasses a major portion of the "painful bladder” disease complex, which includes a large group of urologic patients with bladder and/or pelvic pain, irri tative voiding symptoms (urgency, frequency, nocturia, dysuria), and negative urine cultures. Painful bladder diseases with a well-known cause include radiation cystitis, cyclophosphamide cystitis, cystitis caused by microorganisms that are not detected by routine culture methodology, and systemic diseases affecting the bladder.
  • the median age of onset is 40 years. Up to 50% of patients experience spon taneous remissions probably unrelated to treatment with a duration ranging from 1 to 80 months (mean 8 months). Patients with IC are 10 to 12 times more likely than con trols to report childhood bladder problems.
  • DMSO is a product of the wood pulp industry and a derivative of lignin. It has exceptional solvent properties and is freely miscible with water, lipids, and organic agents. Pharnacologic properties include membrane penetration, enhanced drug absorption, anti-inflammatory proper ties, analgesic properties, collagen dissolution, muscle relaxation, and mast cell his tamine release. In vitro effects on bladder function belie its positive effects in vivo. (Source: Walsh: Campbell's Urology, 7th ed., Copyright.COPYRGT. 1998 W. B. Saunders Company).
  • Oral mucositis is a significant problem in patients receiving chemothera py or radiation therapy.
  • Estimates of oral mucositis in cancer therapy range from 40% of those receiving standard chemotherapy to 76% of bone marrow transplant patients. Virtually all patients who receive radiation therapy to the head and neck ar ea develop oral complications.
  • OM Up to 90% of hematopoietic stem cell transplant pa tients develop OM; up to 77% of breast cancer patients develop OM; up to 68% of head and neck cancer patients receiving chemotherapy develop OM; up to 63% of colorectal cancer patients develop OM; up to 58% of esophageal cancer patients de velop OM; up to 43% of malignant lymphoma patients develop OM; and up to 38% of non-small cell lung cancer patients develop OM.
  • Patients receiving targeted therapy will develop OM with an incidence of up to 78% for Everolimus, up to 41 % for Temsirolimus, up to 37% for Sunitinib, and up to 24% for Trastuzumab.
  • Additional targeted therapeutics associated with the risk of developing OM include bevaci- Kursab, cetuximab, erlotinib, gefitinib and sorafenib.
  • Mucositis is not only painful, but it also can limit adequate nutritional intake and decrease the willingness of patients to continue treatment. More severe mucosi tis with extensive ulceration may require costly hospitalizations with parenteral nutri tion and narcotics. Mucositis diminishes the quality of life and may result in serious clinical complications.
  • a healthy oral mucosa serves to clear microorganisms and provides a chemical barrier that limits penetration of many compounds into the epi thelium.
  • a mucosal surface that is damaged increases the risk of a secondary infec tion and may even prove to be a nidus for systemic infection. Mucositis may result in the need to reduce dosage in subsequent chemotherapy cycles or to delay radiation therapy, which may ultimately affect patient response to therapy.
  • chemotherapeutic drugs that produce direct stomatotoxicity include the alkylating agents, antimetabolites, natural products, and other synthetic agents such as hydroxyurea and procarbazine hydro chloride. Typical sequelae of these cytotoxic agents include epithelial hyperplasia, collagen and glandular degeneration, and epithelial dysplasia. Mucositis is an inevi table side effect of radiation.
  • the severity of the mucositis is dependent on the type of ionizing radiation, the volume of irradiated tissue, the dose per day, and the cumu lative dose. As the mucositis becomes more severe, pseudomembranes and ulcera tions develop. Poor nutritional status further interferes with mucosal regeneration by decreasing cellular migration and renewal.
  • a mucositis grading system gives the physician the ability to assess the severi ty of the mucositis in terms of both the pain and the patient's ability to maintain ade quate nutrition so that a treatment plan can be appropriately constructed.
  • An example of a common grading system is that proposed by the National Cancer Institute, which uses a number ing scale of 0 to 4.
  • Grade 0 means no mucositis; grade 1 , the patient has painless ulcers, erythema, or mild soreness; grade 2, the patient has painful erythema, ede ma, or ulcers but can eat solid food; grade 3, the patient has painful erythema, ede ma, or ulcers and cannot eat solid food; and grade 4, the patient requires parenteral or enteral support.
  • a standardized approach for the prevention and treatment of chemotherapy- and radiation-induced mucositis is essential; unfortunately, the efficacy and safety of most of the regimens have not been established.
  • the prophylactic measures usually employed for the prevention of mucositis include chlorhexidine gluconate (Peridex), saline rinses, sodium bicarbonate rinses, acyclovir, amphotericin, and ice.
  • Regimens commonly used for the treatment of mucositis and its associated pain include a local anesthetic such as lidocaine or Dyclone, Maalox or Mylanta, diphenhydramine (Ben adryl), nystatin, or sucralfate.
  • agents are either used alone or in different combinations of the above medications made into a mouthwash.
  • Other agents used less commonly include Kaopectate, allopurinol, vitamin E, beta-carotene, Kamillosan liquid, aspirin, antiprostaglandins, prostaglandins, MGI 209 (marketed as Oratect Gel), silver nitrate, and antibiotics.
  • Oral and sometimes parenteral narcotics are used for pain relief.
  • a new method utilizing capsaicin is currently under study to help re lieve the pain. (Source: DeVita: Cancer: Principles and Practice of Oncology, 5th ed., Copyright.COPYRGT. 1997 Lippincott-Raven Publishers).
  • Lichen planus is a common, idiopathic skin disorder affecting approxi mately 2% of the adult US population. Although its behavior on the skin is predicta ble and manageable using topical corticosteroids, oral lichen planus (OLP) has a more variable clinical course and is less responsive to topical corticosteroid therapy. There are multiple clinical presentations of OLP, and the disorders in some of these clinical forms can mimic many other types of oral lesions. Furthermore, some au thors believe that certain clinical types of OLP may have a premalignant nature. Var ious drugs, topical and systemic, have been shown to induce lichenoid lesions through antigenic mechanisms.
  • LP reticular form
  • These lesions appear as raised white, linear striations that often interlace in what is termed striae of Wickham. These striations are almost pathognomonic of the disorder. It should be noted that these linear lesions also accompany the erosive form of OLP and occur at the periphery of the eroded area. This is a significant diagnostic clue in the evalua tion of the erosive type.
  • the reticular form usually is observed on the buccal mucosa, often bilaterally. Several authors have noted that these lesions are adjacent to gold or silver amalgam restorations in many cases. The lesions are asymptomatic.
  • the bullous form of OLP is uncommon, perhaps because the oral cavity is a very active region. The functions of chewing, swallowing, and speaking probably do not allow the bulla to remain intact for very long. The size of these lesions is variable, from a few millimeters to several centimeters.
  • the plaque type of OLP appears as a nondescript leukoplakia that needs to be biopsied if no other diagnosis can be made for the lesion. These lesions appear as multiple diffuse, raised white plaques com monly on the buccal mucosa and tongue. Silverman et al have determined that pa tients with this form of LP tend to be smokers. This may place them at risk for trans formation to dysplasia or carcinomatous change.
  • OLP atrophic form of OLP can be seen concomitantly with the erosive or reticu lar forms. This is frequently the type of OLP seen on the gingiva of patients, com- monly referred to as desquamative gingivitis. These lesions are symptomatic. The patient may complain of burning and pain while brushing. Because dental plaque has been implicated as a possible antigen, the patient will need to see a dentist for pro professional maintenance following initial corticosteroid treatment of the lesions.
  • Erosive LP is the most painful form of OLP. As stated previously, these ero sions are seen frequently with the reticular form adjacent to the area. Atrophic or plaque forms may be seen less commonly. Erosive LP may mimic oral cancer, ery thema multiforme, lupus erythematosus, and candidiasis. Many drugs can produce lesions that look like erosive LP clinically. (Source: D. A. Miles and M. M. Howard, "Disorders affecting the oral cavity: Diagnosis and management of oral lichen planus", Dermatologic Clinics, 1996, 14(2), 281 -290.)
  • Pemphigus is a rare, autoimmune blistering disease. Of the various forms of pemphigus, pemphigus vulgaris and paraneoplastic pemphigus affect the oral muco sa with regularity.
  • the antigenic targets in pemphigus are components of the des- mosome. Binding of autoantibodies to these antigenic proteins, desmogleins and desmoplakins, leads to dissolution of intercellular adhesion with resultant blister for mation.
  • Activity of the disease correlates with titers of pemphigus antibody, which can be detected in the serum of patients with the disease by indirect immunofluores cence testing.
  • Pemphigus was often a fatal disease before the use of systemic corticoster oids. It has a chronic course, and control of the disease becomes more difficult with subsequent flares. The basis of treatment is immunosuppression to decrease anti body synthesis. Relapses may occur when immunosuppressive drugs are tapered. Paraneoplastic pemphigus remains a very difficult disease to treat and continues to have very high mortality rates.
  • Intravenously administered cyclophosphamide should be reserved for patients with severe, recalcitrant disease because of the serious complications that may occur during therapy.
  • Source: J. L. Popovsky and C. Camisa “New and emerging therapies for diseases of the oral cavity", Dermatologic Clinics, 2000, 18(1 ), 1 13-125.)
  • Acute complications of pelvic radiation occur with distinct clinical courses and pathologic manifestations.
  • the most frequent serious complication of pelvic radiation is small bowel damage, including thrombocytopenia, leukopenia, dysuria, and effects on the small bowel (diarrhea, abdominal cramping, and increased bowel frequency) and large bowel (acute proctitis, tenesmus, bloody and/or mucus discharge).
  • Sig- moidoscopy during treatment normally reveals an inflamed, edematous, and friable rectal mucosa consistent with acute radiation proctitis. These symptoms are usually transient and resolve within a few weeks following the completion of radiation thera py.
  • Sjogren syndrome is a disorder whose main features are dry eyes and a dry mouth. The condition typically develops gradually beginning in middle adulthood, but it can occur at any age.
  • Sjogren syndrome is classified as an autoimmune disorder, one of a large group of conditions that occur when the immune system attacks the body's own tis sues and organs.
  • the immune system primarily attacks the glands that produce tears (the lacrimal glands) and saliva (the salivary glands), im pairing the glands' ability to secrete these fluids.
  • Dry eyes may lead to itching, burning, a feeling of sand in the eyes, blurry vi sion, or intolerance of bright or fluorescent lighting.
  • a dry mouth can feel chalky or full of cotton, and affected individuals may have difficulty speaking, tasting food, or swallowing. Because saliva helps protect the teeth and the tissues of the oral cavity, people with Sjogren syndrome are at increased risk of tooth decay and infections in the mouth.
  • IBD Inflammatory bowel diseases
  • Crohn's disease are chronic inflammatory diseases of the gastrointestinal tract. They are di agnosed by a set of clinical, endoscopic, and histologic characteristics, but no single finding is absolutely diagnostic for one disease or the other. Moreover, some patients have a clinical picture that falls between the two diseases and are said to have inde terminate colitis.
  • ulcerative colitis The inflammatory response in ulcerative colitis is largely confined to the muco sa and submucosa, but in Crohn's disease the inflammation extends through the in testinal wall from mucosa to serosa. Ulcerative colitis is confined to the colon, and colectomy is a curative procedure. Crohn's disease, in contrast, can involve any part of the gastrointestinal tract, although the distal small bowel and the colon are most commonly involved. Resection of the inflamed segment is not curative in Crohn's disease, and inflammation is likely to recur.
  • ulcerative colitis inflammation begins in the rectum, extends proximally a certain distance, and then abruptly stops, with a clear demarcation between involved and uninvolved mucosa.
  • mild disease there are superficial erosions, whereas in more severe disease, ulcers may be large but superficial, penetrating the muscularis mucosa only in very severe disease.
  • Inflammatory polyps or pseudopolyps may be present.
  • Most of the pathologic findings in ulcerative colitis are limited to the mucosa and submucosa; the muscularis basement is affected only in fulminant disease.
  • Active ulcerative colitis is marked by neutrophils in the mucosa and submucosa and clumps of neutrophils in crypt lumens (crypt abscesses). There is mucus depletion, mucosal edema, and vascular congestion with focal hemorrhage. In addition to signs of acute activity, there are also signs of chronicity, with lymphoid aggregates, plasma cells, mast cells, and eosinophils in the lamina intestinal.
  • ulcerative colitis The dominant symptom in ulcerative colitis is diarrhea, which is usually associ ated with blood in the stool. Bowel movements are frequent but small in volume as a result of irritability of the inflamed rectum. Urgency and fecal incontinence may limit the patient's ability to function in society. Other symptoms include fever and pain, which may be in either lower quadrant or in the rectum. Systemic features-fever, malaise, and weight loss--are more common if all or most of the colon is involved and may have a greater effect than diarrhea on the patient's ability to function. Some patients, especially elderly persons, complain of constipation rather than diarrhea because rectal spasm prevents the passage of stool.
  • ulcerative colitis The initial attack of ulcerative colitis may be fulminant with bloody diarrhea, but more commonly the disease begins indolently, with non-bloody diarrhea progressing to bloody diarrhea. Ulcerative colitis can present initially with any extent of anatomic involvement, from disease confined to the rectum to pancolitis. Most commonly, ulcerative colitis follows a chronic inter mittent course with long periods of quiescence interspersed with acute attacks last ing weeks to months; however, a significant percentage of patients suffer a chronic continuous course. (Source: Goldman: Cecil Textbook of Medicine, 21 st Ed).
  • Additional mucosal disorders useful for treatment using the mucoadhesive compositions of the present invention include vaginal mucositis, mucositis in the stomach, in the intestines, and in other tissues or organs of the alimentary canal where mucositis is occurring. In these cases, it may be advantageous to adjust the composition to obtain relative viscosity of the composition so that it more readily reaches the tissues by oral, rectal or vaginal administration.
  • compositions may be used with or without one or more active pharmaceuti cal agents. These formulations are especially beneficial in diseases and conditions in which a wide area of the mucosal surface requires treatment, but the formulations may also be used in treating small areas of the mucosal surface.
  • mucocutaneous disorders are treated effectively, it is preferred that the lesion is in contact with the liquid mucoadhesive composition for the period of time required to derive benefit.
  • this invention describes mu coadhesive, viscous liquid formulations which may or may not contain one or more pharmaceutically active ingredients.
  • the liquid can readily be applied to the affected region of the mucosa by methods known in the art, while the high viscosity and mu- coadhesion will cause liquid to remain in contact with the lesion for extended peri ods.
  • the formulations of the present invention may be applied to treat mucocutane ous lesions in a variety of body compartments, including, but not limited to, the oral cavity, the nasal cavity, the esophagus, the gastro-intestinal tract, the rectum, the bladder, and the vagina.
  • the viscous, mucoadhesive liquid formulations of the current in vention may be used to deliver one or more pharmaceutically active compounds to the mucosal surface, either for the prevention or treatment of diseases and disorders of the mucosa, or for delivery of the pharmaceutically active compound(s) to the sys- temic circulation by transfer through the mucosa.
  • the present invention discloses an aqueous mucoad hesive and bioadhesive composition for the treatment or prevention of diseases or disorder related to mucous membrane.
  • the aqueous composition may comprise the combination of mucoadhesive agent, bioadhesive agent, a pharmaceutically active agent, natural polymer and cannabinoid.
  • the present invention discloses composition that may be stable from solid to liquid state, and the use of these compositions to coat mucocu taneous surfaces, such as those in the oral cavity, the nasal cavity, the gastrointesti nal and respiratory tracts, the eye, the vagina, and the bladder, etc. to prevent and/or treat mucosal diseases and disorders, including those which are ulcerative, inflam matory, and/or erosive.
  • the present invention discloses the composition wherein the dosage forms are compositions sufficiently used to coat a wide area of the mu cosal surface, but are also bioadhesive and mucoadhesive useful to provide pro longed retention on the surface of the mucosa.
  • the present invention discloses the compositions from liquid to solid may be used without a known pharmaceutically active compound.
  • One or more pharmaceutically active compounds may be included in the composition to provide additional benefit in the topical treatment of diseases, disorders and condi tions of the mucosa, or for drug delivery through the mucosa to the systemic circula tion.
  • an aqueous mucoadhesive and bioadhesive composition comprising all natural ingredi ents for the sustained and effective treatment or prevention of mucosal diseases and disorders.
  • the present invention discloses a composition for the treatment or prevention of mucocutaneous diseases and/or disorders.
  • the aforemen tioned composition of the present invention comprises an amount of a bioadhesive and mucoadhesive effective to coat the mucocutaneous area being treated and may also contain a therapeutically or prophylactically active drug for a mucocutaneous disorder.
  • the aforementioned composi tion described herein is useable in the treatment or prevention of a mucocutaneous disorder.
  • This composition comprises an amount of a bioadhesive and mucoad hesive to form an effective coat in the mucocutaneous area being treated and can include a combination of therapeutic or prophylactic drugs for mucocutaneous disor ders.
  • the mucoadhesive agent disclosed in the present in vention is a naturally occurring compound.
  • the mucoadhesive agent is generally present at a concentration between 0.01 w/w% and about 10.0 w/w% in the afore mentioned composition.
  • the mucoadhesive agent of the pre sent invention is sodium alginate and the preferred bioadhesive is hyaluronic acid.
  • the composition of the present invention is preferably at a pH between about 5.5 and about 8.5. Particularly, sodium alginate is highly effective and suitable in dis closed composition herein.
  • sodium alginate is unique and preferred for a variety of reasons and provides a variety of unexpected benefits to the composition.
  • sodium alginate provides antimicrobial activity to the mucoadhesive composition.
  • sodium alginate provides anti-inflammatory activity. See Maroon et al., Surg. Neurol. Int., 2010, 1 :80, PMCID: PMC301 1 108.
  • Furthermorae sodium alginate is a natural prod uct, and compositions containing greater than 70% wt/wt natural ingredients can be labeled as a“natural” product in the commercial marketing of the mucoadhesive composition.
  • a preferred composition typically contains from 0.01 to 10.0 wt/wt % of sodium alginate, preferably 0.01 to 5.0 wt/wt %, and more preferably about 1 .0 to 2.0 wt/wt %.
  • a particularly preferred composition contains 1 .80 wt/wt % sodium alginate.
  • Sodium alginate has been extensively characterized in the scientific literature, and its preparation and purification has also been described extensively. See, for example, Krol et al, Int.J.Mol.Sci. 2017, 18: 678; Smidsrod, Carbohydrate Research 1973, 27:107; and Huag et al, Acta Chemica Scandinavica 1969, 23: 2955.
  • polyanionic carbohydrate polymers and oligomers can have a beneficial effect in the treatment of mucosal disorders.
  • pentosan poly sulfate and hyaluronic acid are known to provide benefit to patients with interstital cystitis (Morales A, et al, Treatment of refractory interstitial cystitis, Int Urogynecol J Pelvic Floor Dysfunct 1996; 7(4):215-20).
  • other polyanionic and polycationic compounds may also provide benefit in the prevention and treatment of mucosal disorders.
  • Linear and par tially cross-linked polyanionic polymers may be included in the compositionue/‘P 0;sed in the mucoadhesive composition.
  • Additional polymers which are useful in the mucoadhesive composition include carboxy methyl cellulose, hydroxy propyl me thyl cellulose, Carbopol 934, Carbopol 971 , Noveom AA, tragacanth, sodium algi nate, polycarbophil, hydroxyl ethyl cellulose, and the like polymers.
  • the aforementioned composi tion may contain at least 70 % wt/wt natural ingredients such that the composition can be labeled as a“natural” product for marketing purposes under current rules in the US for natural products.
  • This natural designation provides particular advantages, and provides an additional reason for sodium alginate being particularly preferred mucoadhesive ingredient in the mucoadhesive compositions of the present inven tion. This is in contrast to the use of, for example Carbopol 934, Carbopol 971 , Noveom AA, or polyvinylpyrrolidine (PVP), as examples instead, which is a synthetic polymer, as a mucoadhesive.
  • PVP polyvinylpyrrolidine
  • An additional advantage to natural ingredient desig nation is the intrinsic appeal to the health-conscious consumer and to facilitate tar geted marketing to the natural products consumer.
  • Further benefits to a natural product include the placebo effect associated with the patient who uses the mucoad- hesive composition, whereby the patient understands the product is natural and is thereby free from any stress associated negative perceptions about using a muco- adhesive composition containing synthetic polymers or materials.
  • Further ad vantages include the ability to swallow and thereby consume the mucoadhesive composition without any adverse side effects associated with a synthetic composi tion. This is particularly important when a physician or care provider is assessing the risk versus benefit analysis for any particular therapeutic or care plan.
  • flyaluronic Acid is unique and preferred for a variety of reasons and provides a variety of unexpected benefits to the compo sition.
  • Flyaluronic acid is a substance that is naturally present in the human body. It is found in the highest concentrations in fluids in the eyes and joints.
  • Flyaluronic acid (FIA) is a polyanionic polysaccharide that consists of N-acetyl-D-glucosamine and b- glucoronic acid.
  • Flyaluronic acid is the surface-anchored bioadhesive ligand in the composition for its unique viscoelastic nature and a drug delivery agent for ophthal mic, nasal, oral, dermal, pulmonary, intestinal, vaginal, and rectal routes.
  • a drug delivery agent for ophthal mic nasal, oral, dermal, pulmonary, intestinal, vaginal, and rectal routes.
  • For exam ple hyaluronic acid provides wound healing in dermal and mucosal tissues. See Chen M et al; Technical center, Guangzhou Weimeizi Industrial Co., Ltd., Guang zhou 510665, PR China; Collaborative Research Center of Guangzhou Weimeizi In dustrial Co., Ltd and Rutgers University, 2019, PMID: 30465936, DOI: 10.1016/j.archoralbio.2018.10.027
  • a mucoadhesive liquid, solid, semi-solid, gel, gummy or powder composition may contain one or more pharmaceu tically active ingredients including anesthetic, analgesic, antihistamine, antiseptics, antioxidants, anti-fungals, antibacterials, anti-infectives, antiemetics, antidiarrheals, antifungals, anti-inflammatories, antimicrobial agents, astringents, amino acids, cleansing agents, cooling agents, corticosteroids, emollients, flavorants, flavonoids, healing agents, humectants, liposomes, moisturizers, peptides, prebiotics, probiotics, solubilizing agents, styptic agents, sweeteners, vasodilators and other excipients known in the art of composition of pharmaceutical products.
  • the aforemen tioned composition may preferably include a therapeutically or prophylactically effec tive
  • a bioadhesive liquid, solid, semi solid, gel, gummy or powder composition can include plant lectins, nano- hydroxapatite, p-defensin-3 peptide, salamander secretions, snail mucus, fenugreek gum, polysaccharides, fruit sugars, and dextran.
  • other components of the composition may can include sorbic acid, citric acid, glycerin, synsepalum dulcficum, and erythritol or xylitol, alone or in combination with each other and/or the other ex cipients of the compositionmay have a beneficial effect.
  • humec- tants emulsifying agents, amino acids, analgesics, anesthetics, antihistamines, anti septics, antioxidants, anti-fungals, antibacterials, antiemetics, antidiarrheals, anti inflammatory, antimicrobial agents, astringents, bowel obstruction agents, cellular regeneration, cleansing agents, cooling agents, corticosteroids, emollients, flavor- ants, flavonoids, healing agents, humectants, moisturizers, peptides, solubilizing agents, styptic, vasodilators, and other excipients known in the art in the composition of pharmaceutical products, alone or in combination, may also provide for, or en hance, the beneficial properties on mucosal surfaces, when formulated to provide a viscous, mucoadhesive solution.
  • the aforementioned composi tion for the prevention and treatment of mucosal diseases and disorders may addi tionally be formulated with one or more compounds known to be pharmaceutically active. Addition of further pharmaceutically active compounds could provide greater benefit to patients in the prevention and treatment of mucosal disorders. Examples of pharmaceutically active compounds which could be incorporated in the mucoad hesive solutions of this invention as provided later in this section.
  • the aforementioned composi tion may contain a combination of mucoadhesives or other ingredients, in so far as those other ingredients provide desirable properties.
  • the composition may further include chitosan, carrageenan, or hyaluronic, in amounts to contribute to the relative viscosity of the composition, or to provide additional useful properties to the composition.
  • hyaluronic acid is known to promote moisture reten tion and otherwise to provide healing effects and may further contribute to viscosity.
  • Preferred polymer ingredients which contribute to the viscosity and mucoadhesive properties are natural polymers, such as agar, agarose, albumin, alginate, arame, bladderwrack, carrageenan, chitin, chitosan, collagen, dextran, dulse, gum Arabic, gelatin, guar gum, hyaluronic acid, hydroxyl propyl methyl cellulose, irish moss, lec tin, manikara zapota, mastic gum, moringa gum, mytilus edulis, neem gum, nori, pectin, psyllium, sea palm, snail slime or mucus, sodium caroxymethylcellulose, sol uble starch, sunflower lecithin, tamarind seed polysaccharide, tragacanth, xanthum gum, brown seaweed, sodium alginate.
  • natural polymers such as agar, agarose, albumin, alginate
  • the aforementioned composi tion may comprise the combination of sodium alginate and hyaluronic acid.
  • This combination of sodium alginate and hyaluronic acid is preferred because there is a synergistic cellular interaction with this combination that provides an antibacterial ac tivity.
  • This composition preferably includes a ratio of sodium alginate and hyaluronic acid in amounts which provide demonstrable enhancement and controlled release of lidocaine activity.
  • This combination is also particularly preferred because sodium al ginate and hyaluronic acid are natural components, which can contribute to the des ignation of a“natural” product for marketing purposes.
  • Anirudhan et al Department of Chemistry, School of Physical and Mathematical Sciences, University of Huawei, India, Carbohydrate Polymers, 2016 , 152 (2016) 687-698.
  • a further preferable composi tion of a mucoadhesive composition of the present invention comprises sodium algi nate and chitosan is disclosed herein.
  • This combination of sodium alginate and chi tosan is preferred because there is a synergistic cellular interaction with this combi nation that provides an antibacterial activity.
  • This composition preferably includes a ratio of sodium alginate and chitosan in amounts which provide demonstrable antibacterial activity.
  • a preferred composition of a mucoadhesive composition of the pre sent invention comprises sodium alginate and hyaluronic acid (HA).
  • HA hyaluronic acid
  • This combina tion of sodium alginate and HA is preferred because HA contributes moisture reten tion and the capacity to further promote healing to the mucoadhesive composition.
  • This composition preferably includes a ratio of sodium alginate and HA in amounts which provide demonstrable moisture retention or healing activity.
  • sodium alginate and HA are natural compo nents, which can contribute to the designation of a“natural” product for marketing purposes.
  • the aforementioned composi tion may comprise additional combinations which contain natural ingredients can in clude agar, agarose, albumin, alginate, arame, bladderwrack, carrageenan, chitin, chitosan, collagen, dextran, dulse, gum Arabic, gelatin, guar gum, hyaluronic acid, hydroxyl propyl methyl cellulose, irish moss, lectin, manikara zapota, mastic gum, moringa gum, mytilus edulis, neem gum, nori, pectin, psyllium, sea palm, sodium caroxymethylcellulose, soluble starch, sunflower lecithin, tamarind seed polysaccha ride, tragacanth, xanthum gum, brown rice, or a variety of celluolose derivatives. Formulations with one or more of these additional natural ingredients are preferred because as natural components they can contribute to the designation of
  • the aforementioned composi tion may further comprise pharmaceutically active compounds which may be formu lated with the mucoadhesive agent in liquid, semi-solid, gel, gummy, solid in the form of lozenges or powder formulations of the current invention, either for topical treatment of a mucosa, or for transfer of the pharmaceutically active ingredient to the systemic circulation can include, either alone or in combination, one or more of the following classes of drugs: anti-allergy compounds, anti-inflammatory analgesic agents, steroidal and non-steroidal anti-inflammatory agents, anabolic steroids, an algesics, antiemetics, antihistamines, local anesthetics, amino acids, bactericides, cooling agents, cortecosteroids, disinfectants, healing agents, peptides, vasocon strictors, compounds that promote wound-healing, hemostatics, chemotherapeutic agents, antibiotics, keratolytics, cauterizing agents, and antiviral drugs
  • the aforementioned composi tion may further contain one or more cannabinoids as an active ingredient, in an amount to provide a therapeutically or prophylactically effective outcome upon ad ministration of the mucoadhesive composition as described herein, typically in an amount of about 0.01 -15% wt/wt.
  • cannabinoids are cannabidiol (CBD), tetrahydrocannabinol (THC), cannabidiolic acid (CBD-A), cannabigerolic acid (CBN- A), cannabigerol (CBG), cannabinolic acid (CBN-A), cannabichromenic acid (CBC- A), cannabichromene (CBC), and cannabinol (CBN), the structures and preparation of which are described in US Patent 7,807,71 1 .
  • Cannabidiol (CBD) is particularly preferred in view of its antioxidant, anti-inflammatory, anesthetic, antiemetic and an algesic properties that make it useful in the claimed formulations.
  • CBD can be 200extracted from cannabis by a variety of published methods, in particular as described by Giacoppo et al, DARU J Pharma. Sci., 2015, 23:48. Furthermore, cannabinoids and CBD can be obtained from a variety of ven dors in a range of concentrations.
  • a preferred vendor for CBD is FlempMeds PX, LLC, hempmedspx.com, which provides certified pure CBD available as a dried ma terial at 99.8 wt%.
  • a preferred mucoadhesive liquid composition contains 0.01 - 15.0% (wt/wt), preferably about 0.01 -10.0%, and more preferably 0.4% CBD.
  • the mucocutaneous disorders treatable by the methods and compositions of the present invention may include but not limited to oral, vaginal or rectal mucositis, Bechet's disease, apthous ulcer, bullous pemphigoid, chemical cystitis, radiation cystitis, erythema multiforme, esoph agitis, interstitial cystitis, oral Lichen planus, pemphigus, Sjogren’s syndrome, stoma titis, xerostomia, radiation proctitis, stomatopharyngitis, vaginitis, bacterial vaginosis, keratitis sicca, conjunctivitis, dry eye disease, rhinitis, or ulcerative colitis.
  • ulcerative disorders of mucosal surfaces which result as an adverse side-effect in certain therapies, including certain medications treating various diseas es such as rheumatoid arthritis, HIV, such as dental procedures and appliances, chemotherapy, radiation therapy or stem cell transplantation.
  • side- effects include mucositis, esophagitis, and radiation proctitis.
  • Many other ulcerative or inflammatory mucocutaneous diseases are known, including xerostomia, stomati tis (including caused by certain medications or medical and non-medical apparatus’), and the like.
  • the present invention involves a method for the pre vention or treatment of mucocutaneous disorders.
  • This method involves identifying a patient having or possibly developing a mucocutaneous disorder.
  • a composition comprising a bioadhesive and mucoadhesive agent in an amount effective to prevent or treat the mucocutaneous disorder.
  • this composition may and often does include a viscosity- inducing agent and/or a viscosity-enhancing concentration of bioadhesive and mu coadhesive.
  • Mucocutaneous disorders treatable by this method are described above.
  • This composition is often more useful when possessing pseudoplastic behav ior, which provides for reduced viscosity during application, allowing the composition to cover the mucosa more readily, and for increased viscosity of the composition when in place on a mucocutaneous area.
  • this will vary according to the severity and type of disorder. It is expected that the alleviation of mucocutaneous disorders should be visible to anyone treating the patient and that the method of treatment should continue until recovery is clear. This may take from hours to days to weeks, depending upon the situation. Preferred mucoadhesive agents for this method are described herein. Likewise, for viscosity-inducing agents.
  • the aforementioned composi tion described herein are useful for the prevention and treatment of disorders of mu cous membranes in humans and animals.
  • the liquid, semi-liquid, gel, semi-solid, or solid form of other formulations of the present invention are ideally suited to treat diseases and disorders which affect a wide area of the mucosal surface, but they al so provide the opportunity to treat discrete, localized lesions, especially in the oral cavity.
  • the mucous membranes which may be treated by the compositions de scribed in this patent include, but are not limited to, those in the oral cavity, the nasal cavity, the gastrointestinal and respiratory tracts, the eye, the vagina, and the blad- der.
  • Inflammatory, erosive, and/or ulcerative diseases which can be treated by topi cal application of the compositions described in this patent include, but are not lim ited to, aphthous ulcers, Behcet syndrome, bullous pemphigoid, chemical or radia tion-induced cystitis, erythema multiforme, esophagitis, interstitial cystitis, oral or rec tal mucositis, oral lichen planus, pemphigus, rhinitis, conjunctivitis, uveitis dry eye syndrome, vaginitis, bacterial vaginosis, stomatitis, xerostomia, and radiation procti tis.
  • compositions of this invention might be applied prior to the formation of lesions, or at the commencement of therapy to prevent or delay the onset of inflammatory, erosive, and/or ulcerative lesions.
  • the mucoad- hesive/bioadhesive agents are designed to adhere to mucosal tissues thereby creat ing a barrier to protect the tissue.
  • delivering a pain reliever through a mucoad- hesive/bioadhesive enables the tissue to absorb and prolong the release of the pain aid on contact and the patient experiences pain relief.
  • This novel mucoadhesive combined with a natural bioadhesive provide drug retention behavior in the composi tion.
  • Aqueous solutions of pharmaceutically-active compounds are well known in the art as convenient drug delivery formulations. Such formulations are most useful for oral delivery, when the solution is swallowed, and the drug is presented to the stomach and gastrointestinal tract in a form which is amenable to rapid absorption. Aqueous solutions are also used to deliver drugs to mucosal tissue. In general, aqueous solutions used to deliver pharmaceuticals tend to be non-viscous and non- mucoadhesive. For oral delivery, this property is undesirable, as it minimizes the amount of drug which is retained in the oral cavity and esophagus, while maximizing what was delivered to the stomach and gastrointestinal tract.
  • aqueous solutions of pharma- ceutically-active compounds offer the advantage over other dosage forms in that a wide area of the mucosa can be readily covered with the solution, which is of benefit if the area to be treated is not a single, discrete region.
  • mucosa not readily ac cessible can be treated using aqueous solutions of pharmaceutically-active com pounds and simple methods of application.
  • formulations which are non- mucoadhesive are less than ideal for delivery of drugs to mucosal surfaces. Such solutions will be rapidly removed from the area being treated, for example, because the liquid flows from the site of application under the influence of gravity, and/or be cause the natural secretions of mucosal membranes carry the solution from the site of application.
  • Mucoadhesive formulations are well known in the art.
  • known formu lations intended for extended drug delivery to (or close to) the site of application of a mucoadhesive composition are either solids or semi-solids.
  • the former include tablets, powders, lozenges, gummies, and films.
  • mucoadhesive semi-solids include gels, gummies, pastes, ointments, and creams. Few, if any, ex amples are known in which a mucoadhesive is used as a drug delivery system.
  • the stable, viscous, mucoad hesive liquid composition disclosed in the present invention may be applied to muco sal membranes for the delivery of pharmaceutically active compounds to the muco sal membranes for prevention and/or treatment of disorders or diseases of these membranes, or for the delivery of pharmaceutically active compounds to systemic circulation by passage through the mucosal membrane.
  • the liquid may be applied, e.g., to the following mucosal surfaces; the oral cavity, the nasal cavity, the gastroin testinal and respiratory tracts, ocular, rectal tissues, the vagina, and/or the bladder.
  • the formulations of the current invention may also be applied to other mucous mem branes for the prevention and treatment of disorders and diseases. Many methods known in the art for the delivery of liquids to body compartments may be used.
  • the preferred stable mucoadhesive liquid, semi-solid, gummy and solid lozenge or powder composition of the present invention may be taken by mouth and distributed throughout the oral cavity by a swishing action, suck- ing, or by the patient adopting a slow circulating movement of the head. Excess solu tion can either be swallowed or expelled.
  • the stable, mucoadhesive liquid composition of the present invention can be swallowed with minimal contact of the oral cavity, or admin istered by gavage, or by spraying the liquid into the throat.
  • the stable, mucoadhesive liquid composition of the present invention can be delivered as droplets or by spraying the liquid into the nose.
  • the stable, mucoadhesive liquid composition of the cur rent invention can be delivered by intravesical or encapsulated administration.
  • the stable mucoadhesive liquid composition of the current invention can be delivered as droplets into the eye.
  • the stable, mucoadhesive liquid, solid, or semi-solid composition of the present invention can be administered by catheter, enema or suppository.
  • a mu coadhesive liquid composition can be administered by topical treatment.
  • pharmaceutically active com pounds which may be formulated with the bioadhesive in liquid, semi-solid, gel, gummy, solid in the form of lozenges or powder composition disclosed herein, either for topical treatment of a mucosa, or for transfer of the pharmaceutically active in gredient to the systemic circulation can include, either alone or in combination, one or more of the following classes of drugs: anti-allergy compounds, anti-inflammatory analgesic agents, steroidal and non-steroidal anti-inflammatory agents, anabolic steroids, analgesics, antiemetics, antihistamines, local anesthetics, amino acids, bactericides, cooling agents, cortecosteroids, disinfectants, healing agents, lipo somes, peptides, prebiotics, probiotics, vasoconstrictors, compounds that promote wound-healing, hemostatics, chemotherapeutic agents, antibiotics, keratolytics, cau terizing agents, and antiviral
  • anti-allergy compounds anti-
  • particular preferred formula tions include analgesics or other pain reliever components, including the local anes thetics mentioned herein below, but in particular further including natural pain reliev ers.
  • exemplary natural anti-inflammatory agents useful for pain relief are well known in the art. See for example, Maroon et al., Natural anti-inflammatory agents for pain relief, Surgical Neurology International. 2010; 1 :80. doi:10.4103/2152-7806.73804.
  • Preferred natural analgesics include peppermint essential oil, willow bark powder, boswellia, menthol, curcumin, tulsi, cayenne, or turmeric extract or turmeric powder in amounts sufficient to provide analgesic benefits.
  • examples of anti-inflammatory analgesic agents include acetaminophen, methyl salicylate, monoglycol salicylate, aspirin, mefenamic acid, flufenamic acid, indomethacin, diclofenac, alclofenac, diclofenac sodium, ibuprofen, ketoprofen, naproxen, pranoprofen, fenoprofen, sulindac, fenclofenac, clidanac, flurbiprofen, fentiazac, bufexarnac, piroxicam, phenylbutazone, oxyphenbutazone, clofezone, pentazocine, mepirizole, tiaramide hydrochloride, etc.
  • the anti-inflammatory agent can be one or more of the natural products Aloe Vera, Boswellia Oil/Extract, Cannabinoids (Cannabidiol Oil), Beta Glucan (1 ,3), Ginger, Glutamine, Honey, L-carnitine, Lemon Extract, Olive Leaf Extract, Tulsi (Holy Basil Oil), Witch Hazel, Green Tea, Licorice (root extract), Calendula, Bee Propolis, Glucosamine, Goji Berry Extract, Myricetin, Chamomile, Hesperidin, Lemon Balm, Coffee, Turmeric, etc.
  • examples of anabolic steroids include testosterone and oxandrolone.
  • examples of antihistamines include diphenhydramine hydrochloride, diphenhydramine salicylate, diphenhydra mine, chlorpheniramine hydrochloride, chlorpheniramine maleate, isothipendyl hy drochloride, tripelennamine hydrochloride, promethazine hydrochloride, methdilazine hydrochloride, cetirizine, brompheniramine, clemastine, fexofenadine, loratadine, etc.
  • examples of analgesics in clude menthol, boswellia oil extract, aspirin, ibuprofen, naproxen, dextromethorphan, NSAIDS, bovine colostrum, cyclosporine A, hops, mustard oil, black cumin, turmeric, willow bark extract, wintergreen oil, myricetin, and the like.
  • examples of local anesthetics include dibucaine hydrochloride, dibucaine, lidocaine hydrochloride, lidocaine, ben- zocaine, p-buthylaminobenzoic acid 2-(die-ethylamino)ethyl ester hydrochloride, pro caine hydrochloride, cetacean, oraqix, tetracaine, tetracaine hydrochloride, carba- mazepine, dibucaine, dibucaine hydrochloride, chloroprocaine hydrochloride, oxyprocaine hydrochloride, mepivacaine, cocaine hydrochloride, piperocaine hydro chloride, dyclonine, dyclonine hydrochloride, bupivacaine, butamben, cannabanoids, carbamazepine, ketamine, nupercainal, oxybuprocaine, prilocaine, pramoxine
  • examples of bactericides and disinfectants include thimerosal, phenol, thymol, benzalkonium chloride, benzethoni- um chloride, chlorhexidine, povidone iodide, cetylpyridinium chloride, eugenol, miconazole nitrate, hydrogen peroxide, trimethylammonium bromide, aloe vera, beta glucan 1 , 3, honey, lemon extract, olive leaf extract, peppermint oil, sorbic acid, bos wellia oil/extract, calendula, lactobacillus acidophilus, lemon extract, maitake, Manu ka honey, lemongrass extract/oil, neem extract/oil, olive leaf, tea tree oil, turmeric, moringa seed extract, snail mucus, etc.
  • examples of vasodilators in clude naphazoline nitrate, tetrahydrazoline hydrochloride, oxymetazoline hydrochlo ride, phenylephrine hydrochloride, tramazoline hydrochloride, L- Citrulline L-Arginine etc.
  • examples of hemostatics in clude thrombin, phytonadione, protamine sulfate, aminocaproic acid, tranexamic ac id, carbazochrome, carbaxochrome sodium sulfanate, rutin, hesperidin, etc.
  • examples of chemotherapeu tic drugs include sulfamine, sulfathiazole, sulfadiazine, homosulfamine, sulfisoxa- zole, sulfisomidine, sulfamethizole, nitrofurazone, taxanes, platinum compounds, topoisomerase I inhibitors, and anthracycline, etc.
  • examples of antibiotics in clude penicillin, meticillin, oxacillin, cefalotin, cefalordin, erythromeycin, lincomycin, tetracycline, chlortetracycline, oxytetracycline, metacycline, chloramphenicol, kana- mycin, streptomycin, gentamicin, bacitracin, cycloserine, and clindamycin.
  • examples of antibacterials in clude aloe vera, beta glucan 1 ,3, honey lemon extract, olive leaf extract, peppermint, sorbic acid, benzalkonium chloride solution, benzoic acid, hydrogen peroxide, miconazole nitrate, etc.
  • examples of antifungals in clude aclovir, fluconazole, diflucan, chlorhexidine, clotrimazole, fungi zone, miconazole nitrate, nystatin, candicidin, fungizone, nystatin, voriconazole, posaconazole, itraconazole, tea tree oil, black walnut, cinnamon, elecampane, garlic, oregano oil, l-histidine, melaleuca oil, mycology, olive leaf oil, rose oil, palmerosa oil, propolis, tulsi oil, menthol, pau d’ arco, peppermint, lemon, petitgrain oil, citronella oil, etc.
  • examples of keratolytics in clude salicylic acid, podophyllum resin, podolifox, and cantharidin.
  • examples of cau terizing agents include the chloroacetic acids and silver nitrate.
  • examples of antiviral drugs include protease inhibitors, thymadine kinase inhibitors, sugar or glycoprotein syn- thesis inhibitors, structural protein synthesis inhibitors, attachment and adsorption inhibitors, and nucleoside analogues such as acyclovir, penciclovir, valacyclovir, ganciclovir, sage, elderberry, ginger, licorice, oregano, green tea, apple cider vine gar, astragalus root, lemon balm, turmeric, etc.
  • examples of acid neutralizing compounds include potassium citrate, calcium carbonate, sodium lactate, calcium acetate, sodium bicarbonate, citric acid, magnesium hydroxide, aluminum hydroxide, etc.
  • examples of anti-allergy com pounds include alopatadine, astemizole, cromolyn, fenpiprane, repirinast, tranilast, traxanox, etc.
  • examples of compounds that promote wound healing are N-acetylcysteine (NAC), dexpanthenol, and the like. See for example Oguz et al, Int Surg 2015, 100:656.
  • a preferred liquid mucoad- hesive composition formulated for use as a topical treatment of rectal mucositis con tains from 0.1 % to 5% of the wound healing compound, and more preferably con tains either 3% NAC or 2.0-3.0% dexpanthenol.
  • the amount of pharmaceuti cally active compound(s) to be used depends on the desired treatment strength, alt hough preferably, the pharmaceutical component comprises 0.001 to 30% by weight of the formulation, and more preferably between 0.005 and 20% by weight.
  • the composition for the prevention and treatment of muco sal diseases and disorders, and for use of the composition as a drug delivery vehi cle, that the liquid, solid, semi-solid, gel, gummy or powder solution be stable, such that it can be stored at ambient temperatures for many months or years, even when subjected to brief periods of elevated or depressed temperatures, without significant physical or chemical degradation of the formulation. It is usually desirable to formu late the product without use of any organic solvents, the presence of which might irri tate the mucosal lesions being treated.
  • a naturally occurring linear or cross-linked polymer polyanionic or polycationic polymer which may or may not already be known to provide mucoadhesion include (but are not limited to) carboxymethylcellulose, hydroxyalkylcellulose, dextran sul fate, dermatan sulfate, and hyaluronic acid.
  • Other mucoadhesive polymers are well- known to those skilled in the art.
  • the mucoadhesive formulations of the current in vention can contain a single mucoadhesive component, or mixtures thereof.
  • the pre ferred mucoadhesive polymer is sodium alginate.
  • Viscosity enhancement is provided by one or more of the above mentioned mucoadhesive polymers alone or in combi nation with agar, bentonite, glycerin, povidone, kaolin, and/or tragacanth.
  • the pH of the solution is ad justed to the final desired pH with any pharmaceutically accepted acid or base.
  • any pharmaceutically accepted acid or base Most preferred are sodium or potassium hydroxide, phosphoric acid, or citric acid.
  • a final pH of 5.5 to 8.5 is preferred.
  • Preserva tives known in the art include benzyl alcohol, benzoate salts, phenoxyethanol, methylparaben, propylparaben, sorbitol and sorbic acid. Sorbic acid is the preferred preservative.
  • a humectant is desirable to provide a pleasant mouth-feel in oral applications.
  • Humectants known in the art in clude cholesterol, fatty acids, glycerin, lauric acid, magnesium stearate, pentaerythri- tol, propylene glycol, hyaluronic acid, honey, avocado oil, olive oil, cinnamon oil, co conut oil, emu oil, flaxseed oil, hemp oil, grape seed oil, jojoba, moringa oil, myrrh oil, frankincense oil, oregano oil, seabuckthorn oil, peppermint oil, spearmint oil, sun flower oil, tea tree oil, thyme essential oil, vitamin a, vitamin c, vitamin e etc.
  • Glycerin is preferred.
  • an emulsifying agent might be necessary, for example to ensure complete dissolution of all excipients, especially hydrophobic components such as hyaluronic acid.
  • hydrophobic components such as hyaluronic acid.
  • Many emulsifiers are known in the art.
  • the preferred emulsifier is hyaluronic acid.
  • a pharmaceutically acceptable flavoring agent and/or sweetener for oral applications, it may be desirable to add a pharmaceutically acceptable flavoring agent and/or sweetener.
  • Compounds such as saccharin, glycerin, simple syrup, erythritol, sorbitol and xylitol are useful among those as sweeteners. Erythritol or Xylitol is preferred.
  • a pharmaceutically acceptable organic solvent for example a pharmaceutically acceptable organic solvent, a buff- ering agent, an antioxidant, an antimicrobial agent, acid-reducing and/or a coloring agent.
  • a pharmaceutically acceptable organic solvent for example a pharmaceutically acceptable organic solvent, a buff- ering agent, an antioxidant, an antimicrobial agent, acid-reducing and/or a coloring agent.
  • a pharmaceutically acceptable organic solvent for example a pharmaceutically acceptable organic solvent, a buff- ering agent, an antioxidant, an antimicrobial agent, acid-reducing and/or a coloring agent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition mucoadhésive et bioadhésive aqueuse destinée au traitement de maladies mucosiques, et l'utilisation de ces compositions pour revêtir des surfaces mucocutanées, telles que celles dans la cavité buccale, la cavité nasale, les tractus gastro-intestinaux et respiratoires, l'œil, le vagin, et la vessie, etc. pour empêcher et/ou traiter les maladies et les troubles des muqueuses, comprenant ceux qui sont douloureux, ulcératifs, inflammatoires, et/ou érosifs. Les formes posologiques sont des compositions suffisamment utilisées pour revêtir une large surface de la surface des muqueuses, mais également sont bioadhésives et mucoadhésives utiles pour fournir une rétention prolongée sur la surface de la muqueuse. Les compositions de liquide à solide peuvent être utilisées sans composé pharmaceutiquement actif connu. Un ou plusieurs composés pharmaceutiquement actifs peuvent être inclus dans la formulation pour fournir un avantage additionnel dans le traitement topique des maladies, troubles et conditions de la muqueuse, ou pour l'administration de médicament à travers la muqueuse à la circulation systémique.
PCT/IB2019/050971 2018-02-06 2019-02-06 Composition mucoadhésive et bioadhésive aqueuse destinée au traitement Ceased WO2019155389A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862626777P 2018-02-06 2018-02-06
US62/626,777 2018-02-06

Publications (1)

Publication Number Publication Date
WO2019155389A1 true WO2019155389A1 (fr) 2019-08-15

Family

ID=67548857

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/050971 Ceased WO2019155389A1 (fr) 2018-02-06 2019-02-06 Composition mucoadhésive et bioadhésive aqueuse destinée au traitement

Country Status (1)

Country Link
WO (1) WO2019155389A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112402397A (zh) * 2019-08-20 2021-02-26 株式会社艾福瑞特 口腔粘膜附着力优异的缓释型口腔崩解用膜及其制备方法
CN112826810A (zh) * 2021-01-27 2021-05-25 西安交通大学 一种预防经皮置管导管外表面感染的联合杨梅素/唑类药物的涂膜剂及其应用
CN112891515A (zh) * 2021-03-30 2021-06-04 云南农业大学 一种辣木凝集素的成分应用
CN113116870A (zh) * 2019-12-31 2021-07-16 四川大学 大麻二酚在制备促进口腔黏膜愈合的药物中的应用
WO2021211381A1 (fr) * 2020-04-13 2021-10-21 Per Os Biosciences, Llc Compositions et procédés de soins bucco-dentaires
IT202000014911A1 (it) * 2020-06-22 2021-12-22 Neilos S R L Composizione per la prevenzione e il trattamento delle affezioni vaginali
WO2022096705A1 (fr) * 2020-11-06 2022-05-12 Handelsselskabet Af 20.10.2020 Aps Traitement de fibrose induite par un rayonnement
WO2022135322A1 (fr) * 2020-12-25 2022-06-30 姜秉均 Nanocomposite contenant une substance hydrophobe, son procédé de préparation et son utilisation
WO2023279137A1 (fr) * 2021-07-07 2023-01-12 Breathe Life Sciences Pty Ltd Composition et application associée
CN117084968A (zh) * 2023-08-21 2023-11-21 上海萌凯医药科技有限公司 一种治疗放射性直肠炎的温敏凝胶及其制备工艺
EP4316535A1 (fr) 2022-08-02 2024-02-07 Marija Glavash Dodov Composition de cicatrisation de plaies contenant du mucus d'escargot
WO2024144613A1 (fr) * 2022-12-28 2024-07-04 Istanbul Medipol Universitesi Teknoloji Transfer Ofisi Anonim Sirketi Formulations en spray nasal comprenant des associatons d'huiles essentielles à base de plantes
RU2824359C1 (ru) * 2023-12-06 2024-08-07 Акционерное Общество "Свобода" (Ао "Свобода") Композиция ополаскивателя для полости рта для детей
WO2025067622A1 (fr) * 2023-09-27 2025-04-03 Fertin Pharma A/S Cannabidiol destiné à être utilisé dans l'atténuation de la xérostomie

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006103418A1 (fr) * 2005-03-28 2006-10-05 Orexo Ab Nouvelles compositions pharmaceutiques utiles dans le traitement de la douleur
WO2006103407A2 (fr) * 2005-03-28 2006-10-05 Orexo Ab Compositions pharmaceutiques convenant pour le traitement de la migraine
US20160228490A1 (en) * 2012-10-29 2016-08-11 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucusal tissue disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006103418A1 (fr) * 2005-03-28 2006-10-05 Orexo Ab Nouvelles compositions pharmaceutiques utiles dans le traitement de la douleur
WO2006103407A2 (fr) * 2005-03-28 2006-10-05 Orexo Ab Compositions pharmaceutiques convenant pour le traitement de la migraine
US20160228490A1 (en) * 2012-10-29 2016-08-11 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucusal tissue disorders

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112402397A (zh) * 2019-08-20 2021-02-26 株式会社艾福瑞特 口腔粘膜附着力优异的缓释型口腔崩解用膜及其制备方法
CN113116870A (zh) * 2019-12-31 2021-07-16 四川大学 大麻二酚在制备促进口腔黏膜愈合的药物中的应用
WO2021211381A1 (fr) * 2020-04-13 2021-10-21 Per Os Biosciences, Llc Compositions et procédés de soins bucco-dentaires
WO2021260546A1 (fr) * 2020-06-22 2021-12-30 Neilos S.r.l. Composition pour la prévention et le traitement de maladies vaginales
IT202000014911A1 (it) * 2020-06-22 2021-12-22 Neilos S R L Composizione per la prevenzione e il trattamento delle affezioni vaginali
WO2022096705A1 (fr) * 2020-11-06 2022-05-12 Handelsselskabet Af 20.10.2020 Aps Traitement de fibrose induite par un rayonnement
WO2022135322A1 (fr) * 2020-12-25 2022-06-30 姜秉均 Nanocomposite contenant une substance hydrophobe, son procédé de préparation et son utilisation
US12533322B2 (en) 2020-12-25 2026-01-27 Bing-Juin CHIANG Nanoparticle containing hydrophobic substance and manufacturing process and use thereof
CN112826810A (zh) * 2021-01-27 2021-05-25 西安交通大学 一种预防经皮置管导管外表面感染的联合杨梅素/唑类药物的涂膜剂及其应用
CN112891515A (zh) * 2021-03-30 2021-06-04 云南农业大学 一种辣木凝集素的成分应用
WO2023279137A1 (fr) * 2021-07-07 2023-01-12 Breathe Life Sciences Pty Ltd Composition et application associée
EP4316535A1 (fr) 2022-08-02 2024-02-07 Marija Glavash Dodov Composition de cicatrisation de plaies contenant du mucus d'escargot
WO2024144613A1 (fr) * 2022-12-28 2024-07-04 Istanbul Medipol Universitesi Teknoloji Transfer Ofisi Anonim Sirketi Formulations en spray nasal comprenant des associatons d'huiles essentielles à base de plantes
CN117084968A (zh) * 2023-08-21 2023-11-21 上海萌凯医药科技有限公司 一种治疗放射性直肠炎的温敏凝胶及其制备工艺
WO2025067622A1 (fr) * 2023-09-27 2025-04-03 Fertin Pharma A/S Cannabidiol destiné à être utilisé dans l'atténuation de la xérostomie
RU2824359C1 (ru) * 2023-12-06 2024-08-07 Акционерное Общество "Свобода" (Ао "Свобода") Композиция ополаскивателя для полости рта для детей

Similar Documents

Publication Publication Date Title
US7547433B2 (en) Liquid formulations for the prevention and treatment of mucosal diseases and disorders
US6828308B2 (en) Compositions and methods for the treatment or prevention of inflammation
KR100761051B1 (ko) 점막염, 구내염 및 베체트 증후군 치료용 약학적 조성물
EP2037941B1 (fr) Compositions de cobalamine destinés au traitement ou à la prévention de mucosite
AU719257B2 (en) Use of hyaluronic acid and a NSAID for the manufacture of a medicament for the treatment of mucosal diseases
US20020103219A1 (en) Stable viscous liquid formulations of amlexanox for the prevention and treatment of mucosal diseases and disorders
CA2958864C (fr) Compositions d'excipients pour compositions pharmaceutiques mucoadhesives comprenant une association synergique d'amylopectine, pullulane, acide hyaluronique et xyloglucane
JPH07507054A (ja) ヒアルロン酸とｎｓａｉｄｓ（非ステロイド系抗炎症剤）を含有する局所用組成物
ES2959546T3 (es) Composición líquida para su uso en el tratamiento de la mucosa del tracto oro-faringo-laringo-esofágico
PT1965787E (pt) Tratamento de xerostomia com um antioxidante que contém enxofre
Nathan Non-prescription medicines
WO2015126841A1 (fr) Formulations mucoadhésives nutritionnelles et thérapeutiques
CN101810861A (zh) 预防和治疗粘膜和皮肤炎症的液体制剂
Boddu et al. Excipients and non-medicinal agents as active pharmaceutical ingredients
JP2723473B2 (ja) 硫酸化糖類の用途
BRPI0902144A2 (pt) processo para preparar uma composição farmacêutica sólida, de administração por via oral que contém os prìncipios ativos glicosamina e meloxicam e uso da associação entre glicosamina e meloxicam
AU2002251967A1 (en) Liquid formulations for the prevention and treatment of mucosal diseases and disorders
HK1126134B (en) Liquid formulations for the prevention and treatment of mucosal diseases and disorders
EP4616843A1 (fr) Composition pharmaceutique destinée à être utilisée dans le traitement de la rectocolite hémorragique et dans le traitement du syndrome de la cystite interstitielle/douleur de la douleur
AU2004222773A1 (en) A method for treatment of mouth lesions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19750940

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19750940

Country of ref document: EP

Kind code of ref document: A1